Loading
Three companies testing three drugs against the same standard treatment each recruit their own control group. Pooling those controls in one shared study would need fewer patients and answer faster.
A neutral academic sponsor runs a master protocol in a defined indication with a single concurrent control arm; each company adds its experimental arm under a pre-agreed data-access and publication charter, paying a per-patient fee. Randomisation is concurrent, so this is a true RCT for each comparison. Precedents include the Lung-MAP and I-SPY structures, but industry-led registrational use is rare.
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Trial design, endpoints and cost, Pancreatic ductal adenocarcinoma.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, Trial design, endpoints and cost.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, Trial design, endpoints and cost.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Trial design, endpoints and cost.
Shares Trials enrol too few, too slowly, Trial design, endpoints and cost, Non-small-cell lung cancer.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Pancreatic ductal adenocarcinoma.